Study aim: Evaluating the safety of sofosbuvir 800mg /Daclatasvir 120 mg in outpatient with COVID (...) tablet of Daclatasvir 60 mg/sofosbuvir 400 mg twice per day (total of Daclatasvir 120 mg/sofosbuvir 800 (...) old Inclusion criteria: Diagnosis of COVID 19 Patients that do not need to be admitted in hospital

Study aim: Evaluation of the Safety and Efficacy of Sofosbuvir in patients with moderate COVID19 (...) Shohada Hospital. Patients will be randomly assigned to the national protocol with or without sofosbuvir (...) air or the Pa02/Fi02 ratio ≤300mgHg , Laboratory (RT-PCR) confirming the infection with 2019-Covid

Study aim: Evaluating efficacy and safety of sofosbuvir/ledipasvir in treatment of COVID-19 Design (...) sofosbuvir/ledipasvir in treatment of COVID-19. Fifty eligible patients will be assigned to intervention or (...) sofosbuvir/ledipasvir 400/90 mg daily for 10 days. The control group will only receive the recommended

Study aim: Determination of efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2 (...) Exclusion Criteria: Participation in any other clinical trial of an experimental trial for COVID-19 History of taking other antivirals aginst COVID-19 in the last 24 hours at the enrollment in the study Multi

Study aim: Comparison of the effectiveness and safety of the addition of Sofosbuvir plus Velpatasvir to standard treatment regimens in patients with COVID-19 Design: This study is one blinded clinical trial. The study population will be all patients infected with COVID-19 admitted to Golestan

Study aim: Comparison of the effect of two drugs Daclatasvir + Sofosbuvir and Ribavirin in COVID (...) clinical trial. The study population includes all patients with COVID-19 referring to Abadan hospitals. All (...) severe symptoms of COVID-19 who were admitted to the infectious ward of Ayatollah Taleghani Hospital in

Study aim: Comparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”, and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19 (...) with COVID-19 admitted to Golestan hospital of Kermanshah. 80 eligible patients will be selected

Study aim: To evaluate whether Sovodak (Sofosbuvir plus Daclatasvir) plus ribavirin increases (...) moderate COVID-19 Design: This is a parallel 2-arm randomized, controlled, double-blind, single center (...) will be blinded Participants/Inclusion and exclusion criteria: All mild to moderate COVID-19 infected

Study aim: Determination of the effect of sofosbuvir/daclatasvir in COVID-19 patients Design: A (...) at any one time, Dry cough, Severe fatigue, Dyspnea, CT appearance compatible with COVID, O2Sat 94 (...) , Previous sofosbuvir use, Pregnancy/lactation, Multi-organ failure on admission (2 organs or more, excluding

Study aim: Determination of the efficacy of daclatasvir + sofosbuvir in patients with COVID-19 Design: Using a table of random numbers, they are divided into intervention and control groups. The (...) Daclatasvir / Sofosbuvir tablet daily for 7 days in addition to the national recommendations, and the control

Study aim: To evaluate whether (Sofosbuvir ) increases significant clinical improvement as compared to standard of care in out patients patients with mild COVID-19 Design: This is a parallel 2-arm (...) drugs, 1 month ago drugs Has received antiviral for Covid-19, is pregnant or lactating, has ESRD

Study aim: To evaluate whether Sovodak (Sofosbuvir plus Daclatasvir) increases significant clinical improvement as compared to standard of care in hospitalized patients with moderate to severe COVID-19. Design (...) treatment group. Participants/Inclusion and exclusion criteria: All moderate to severe COVID-19 infected

Study aim: To compare the rate of treatment failure between sofosbuvir daclatasvir and placebo in ambulatory patients with COVID-19 Design: Randomized, placebo-controlled, quadruple blind multicentre (...) community clinics designated for COVID-19 patients according to the national protocols of the ministry of

Study aim: Determining of adding SOVODAK (sofosbuvir + daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study Design: A clinical trial study will have a control group with a parallel design Settings and conduct: This study will be performed in Miandrood Medical Clinic

: Inclusion criteria: Definitive diagnosis of Covid-19 Age older than or equal to 18 years Inpatients

of patients with COVID-19 admitted in Rasoul Akram and firoozgar hospitals who are under treatment (...) akram and Firoozgar hospitals, covid-19 admission wards for conduct a randomized clinical trial (...) severe admitted stable COVID patients, not any bleeding disorders, no heart attack and stroke, no ocular